2023 annual financial data
Sutro Biopharma 2023 Operating cash flow margin
Direct answer
Operating cash flow margin was -72.6%.
Operating income was -89,278,000 USD and net income was -106,793,000 USD.
Operating cash flow was -111,616,000 USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 153,731,000 USD
- Operating income
- -89,278,000 USD
- Net income
- -106,793,000 USD
- Operating cash flow
- -111,616,000 USD